Literature DB >> 10227640

Myasthenia gravis activities of daily living profile.

G I Wolfe1, L Herbelin, S P Nations, B Foster, W W Bryan, R J Barohn.   

Abstract

The authors have developed an MG activities of daily living (ADL) profile (MG-ADL)-a simple eight-question survey of MG symptoms. In 254 consecutive encounters with established MG patients, the authors compared scores from the MG-ADL to the quantitative MG score (QMG)-a standardized, reliable scale used in clinical trials. The mean MG-ADL score was 4.89+/-3.63. The mean QMG score was 10.80+/-5.70. Pearson's correlation coefficient was 0.583 (p < 0.001). The MG-ADL is an easy-to-administer survey of MG that correlates well with the QMG and can serve as a secondary efficacy measurement in clinical trials.

Entities:  

Mesh:

Year:  1999        PMID: 10227640     DOI: 10.1212/wnl.52.7.1487

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  72 in total

1.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

Review 2.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

3.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Authors:  James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren
Journal:  Neurology       Date:  2019-05-22       Impact factor: 9.910

5.  Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.

Authors:  Xiaoyong Tao; Wei Wang; Feng Jing; Zhongkui Wang; Yuping Chen; Dongning Wei; Xusheng Huang
Journal:  Neurol Sci       Date:  2016-11-21       Impact factor: 3.307

6.  Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.

Authors:  A Uzawa; Y Kojima; Y Ozawa; M Yasuda; Y Onishi; H Akamine; N Kawaguchi; K Himuro; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2020-08-10       Impact factor: 4.330

7.  [Clinical effect of tacrolimus in the treatment of myasthenia gravis in children].

Authors:  Jiu-Wei Li; Fang Fang; Xiao-Tun Ren; Wei-Hua Zhang; Xin-Ying Yang; Chang-Hong Ren; Shuai Gong; Jun-Lan Lyu; Xiao-Hui Wang; Xu Wang; Hu-Sheng Wu; Chang-Hong Ding
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

Review 8.  History of Myasthenia Gravis Revisited.

Authors:  Feza Deymeer
Journal:  Noro Psikiyatr Ars       Date:  2020-11-07       Impact factor: 1.339

9.  Randomized Trial of Thymectomy in Myasthenia Gravis.

Authors:  Gil I Wolfe; Henry J Kaminski; Inmaculada B Aban; Greg Minisman; Hui-Chien Kuo; Alexander Marx; Philipp Ströbel; Claudio Mazia; Joel Oger; J Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Márcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Guillermo S Garcia Ramos; Jan J G M Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Joanne Odenkirchen; Joshua R Sonett; Alfred Jaretzki; John Newsom-Davis; Gary R Cutter
Journal:  N Engl J Med       Date:  2016-08-11       Impact factor: 91.245

10.  Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  Neurol Sci       Date:  2009-10-09       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.